• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎疫苗的安全性、预防策略及患者管理

Safety profile of COVID-19 vaccines, preventive strategies, and patient management.

作者信息

Prabhu M Mukhyaprana, Palaian Subish, Ansari Mukhtar

机构信息

Department of General Medicine, KMC Manipal, MAHE (deemed to be University), India.

Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, United Arab Emirates.

出版信息

Expert Rev Vaccines. 2022 Aug;21(8):1087-1095. doi: 10.1080/14760584.2022.2078311. Epub 2022 May 19.

DOI:10.1080/14760584.2022.2078311
PMID:35559718
Abstract

INTRODUCTION

Fast-track approval has led to serious concerns on the perception of COVID-19 vaccines' safety among the public. Common adverse drug reactions (ADRs) of COVID-19 vaccines are minor localized reactions, while systemic ADRs have been reported rarely. The serious ADRs include anaphylaxis, vaccine-induced immune thrombotic thrombocytopenia syndrome (VITTS), and reactions related to the pharmaceutical excipients present in the vaccine. A comprehensive review on the safety of COVID-19 vaccines would help in early identification and better management of ADRs. This literature review was conducted using PubMed, Google Scholar, COVID-19 Vaccine package inserts, and

AREAS COVERED

This article provides various aspects of COVID-19 vaccine safety and offers strategies to prevent and clinically manage suspected ADRs related to COVID-19 vaccines.

EXPERT OPINION

A careful consideration of contraindications and patient education on early identification of serious ADRs are the cornerstones in tackling safety concerns associated with COVID-19 vaccines. Most of the mild ADR cases are manageable with over-the-counter medications, while the serious ones may require physician oversight and hospitalization. It is also mandatory to report all ADRs to the local pharmacovigilance centers, with a higher priority given to the moe significant ones, in order to improve vaccine safety data.

摘要

引言

快速审批引发了公众对新冠疫苗安全性认知的严重担忧。新冠疫苗常见的药物不良反应(ADR)为轻微的局部反应,而全身性ADR鲜有报道。严重的ADR包括过敏反应、疫苗诱导的免疫性血栓性血小板减少综合征(VITTS)以及与疫苗中存在的药用辅料相关的反应。对新冠疫苗安全性进行全面综述将有助于早期识别和更好地管理ADR。本综述使用了PubMed、谷歌学术、新冠疫苗说明书以及

涵盖领域

本文提供了新冠疫苗安全性的各个方面,并提供了预防和临床管理与新冠疫苗相关的疑似ADR的策略。

专家意见

仔细考虑禁忌症并对患者进行关于早期识别严重ADR的教育是解决与新冠疫苗相关安全问题的基石。大多数轻度ADR病例可通过非处方药处理,而严重病例可能需要医生监督和住院治疗。还必须向当地药物警戒中心报告所有ADR,对于更严重的ADR给予更高优先级,以改善疫苗安全性数据。

相似文献

1
Safety profile of COVID-19 vaccines, preventive strategies, and patient management.新型冠状病毒肺炎疫苗的安全性、预防策略及患者管理
Expert Rev Vaccines. 2022 Aug;21(8):1087-1095. doi: 10.1080/14760584.2022.2078311. Epub 2022 May 19.
2
Global burden of vaccine-associated hepatobiliary and gastrointestinal adverse drug reactions, 1967-2023: A comprehensive analysis of the international pharmacovigilance database.全球疫苗相关肝胆和胃肠道不良药物反应负担,1967-2023:国际药物警戒数据库的综合分析。
J Med Virol. 2024 Jul;96(7):e29792. doi: 10.1002/jmv.29792.
3
French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge.法国新冠疫苗药物警戒组织:一大挑战。
Therapie. 2021 Jul-Aug;76(4):297-303. doi: 10.1016/j.therap.2021.05.003. Epub 2021 May 7.
4
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.评估患者向英国“黄卡计划”报告药物不良反应的情况:文献回顾、描述性和定性分析以及问卷调查。
Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200.
5
Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center.高容量综合癌症中心癌症患者 COVID-19 疫苗的安全性。
Oncologist. 2022 Mar 4;27(2):e203-e205. doi: 10.1093/oncolo/oyab037.
6
Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.强生(Johnson & Johnson)COVID-19 疫苗安全性监测-美国,2021 年 3 月-4 月。
MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):680-684. doi: 10.15585/mmwr.mm7018e2.
7
COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.COVID-19 mRNA 疫苗:一项回顾性观察性药物警戒研究。
Clin Drug Investig. 2022 Dec;42(12):1065-1074. doi: 10.1007/s40261-022-01216-9. Epub 2022 Oct 23.
8
Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.Covid-19 疫苗接种对法国自发药物警戒报告的影响。
Drug Saf. 2023 Dec;46(12):1381-1389. doi: 10.1007/s40264-023-01359-4. Epub 2023 Nov 5.
9
[A retrospective pharmacovigilance analysis: could decreased reporting of suspected adverse reactions generate future safety concerns?].[一项回顾性药物警戒分析:疑似不良反应报告率下降会引发未来的安全担忧吗?]
Recenti Prog Med. 2022 Mar;113(3):198-201. doi: 10.1701/3761.37485.
10
A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.葡萄牙一个药物警戒中心10年活动期间药品不良反应自发报告情况调查。
Int J Pharm Pract. 2014 Aug;22(4):275-82. doi: 10.1111/ijpp.12078. Epub 2013 Nov 5.